Alphamab stake sale could signal harder times ahead
The founder of the cancer drug developer has cashed out part of his holdings after the stock hit a price peak, raising questions about the firm’s earnings outlook Key Takeaways:…
Clinical trials come up short again for Alphamab Oncology
The Chinese pharmaceutical firm has suffered its second clinical setback in a matter of weeks, after its U.S. partner halted trials of a sarcoma drug Key Takeaways: Alphamab Oncology could…
Profit setback for Simcere Pharma in novel drugs quest
The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs Key Takeaways: Simcere Pharmaceutical holds a 9% stake in…
RELATED ARTICLES
-
3SBio hits the big time with $6 billion cancer drug deal
- CSPC Pharma teases big bucks deals after earnings miss
- Investors cheer Akeso’s revenue milestone, even as it returns to the red
- Everest Medicines drives growth with AI-powered mRNA pipeline
- A blockbuster cancer drug? TYK’s claims go under the microscope
- Earnings blow for CSPC Pharma as the state drives a hard bargain
